Skip to Content
A key area of clinical
importance in the field of human genetics is that of gene-drug interactions,
commonly called Pharmacogenomics (PGx). Several gene-drug pairs affecting drug
metabolism and transport have been identified. The most well-studied and validated
of these genes are the Cytochrome P450 (CYP) enzymes, which have a role in the
metabolism of a large number of drugs. Identifying a patient’s DNA profile for
these genes can help determine which drugs at what dose are the most effective
and cause the fewest side-effects.
The Iowa Institute of Human Genetics (IIHG) offers an
integrated drug metabolism (pharmacogenomic) test for clopidogrel (Plavix®)
and opioid medications. The IIHG drug metabolism test can be ordered
preemptively by a physician as a tool in the health care management of their
We have developed a custom multi-gene panel test and
analysis pipeline in collaboration with the University of Iowa Hospitals and
Clinics Department of Pharmaceutical Care, and University of Iowa College of
Pharmacy. The multidisciplinary IIHG-UIHC Pharmacogenomics Team reviews all
results, and the ordering physician receives a report of clinically relevant
results for each patient. Result reports have been developed in collaboration
with UIHC physicians and pharmacists and educational materials are incorporated
into the report to aid health care providers in the interpretation of results.
The IIHG can provide education materials and assistance to the health care
provider so he/she may counsel the patient with confidence.
Did you know?
The IIHG Drug Metabolism Test analyzes gene variants to
allow you to determine prior to surgery if your patient has variants in the CYP2D6 gene that cause them to have
altered opioid metabolism.
The CYP2D6 gene
regulates the metabolism of codeine, and tramadol (Ultram®) for pain
relief. The test looks at DNA changes (variants) in CYP2D6 that can alter the metabolism of opioids. Knowing the type
of CYP2D6 gene your patient has can
help you decide which pain medicine will work best for your patient.
Common indications for testing
The CYP2D6 gene can
also regulate the metabolism of some antidepressants, like tricyclics, and
Tetrabenzine (Xenazine). Please contact the IIHG-UIHC Pharmacogenomics
Stewardship Program if you have questions about the use of the results of this
test for other medications.
Did you know 30% of patients cannot metabolize clopidogrel
due to their DNA variants?
The IIHG Drug Metabolism Test analyzes gene variants to allow
you to determine if your patient has variants in the CYP2C19 gene that prevent them from metabolizing Clopidgrel.
Common indications for testing include:
This is a send out test. To order the test, please complete the following forms which are available on our website:
* All samples must be labeled with the patient's name, date of birth, and date of collection.
After collection, samples should be stored and shipped at room temperature.
Please note: Specimens for which insufficient quality or quantity of
DNA is obtained, an additional sample will be requested. Incorrect
handling or shipping of specimens can result in insufficient quality or
quantity of DNA.
Iowa Institute of Human GeneticsUniversity of Iowa285 Newton Road, 5296 CBRBIowa City, IA 52242Phone: 319-335-3688
*Please note: billing
information MUST be complete before samples will be processed.
Approximately 6 weeks after receipt at the IIHG lab.
Phone: 319-335-3688Pager: 1576Email: firstname.lastname@example.org
Peer-reviewed clinical guidelines published by PharmGKB and
the Pharmacogenomics Research Network
Genetics Home Reference
Information about how
genes affect your health: what genes are, how they work, and how they can cause
The Pharmacogenomics Knowledgebase
Information about how
genes interact with medication
Contact Information Iowa Institute of Human GeneticsUniversity
of Iowa 285 Newton Road, 5296 CBRBIowa City, IA, 52242Telephone: 319-335-3688Fax: 319-335-3484 Email: email@example.com/humangenetics
Courtesy of mendelspod.com